Showing 471-480 of 3494 results for "".
- FDA Approves Ameluz PDT for Superficial Basal Cell Carcinomahttps://practicaldermatology.com/news/fda-approves-ameluz-pdt-for-superficial-basal-cell-carcinoma/2488430/The US Food and Drug Administration (FDA) has approved Biofrontera Inc.’s supplemental New Drug Application for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy (PDT) using the BF-RhodoLED lamp series for the treatment of superficial basal cell
- FDA Grants Priority Review to Zasocitinib for Plaque Psoriasishttps://practicaldermatology.com/news/fda-grants-priority-review-to-zasocitinib-for-plaque-psoriasis/2488421/The US Food and Drug Administration (FDA) has accepted Takeda’s new drug application (NDA) for zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis and granted the application Priority Review, according to a company announcement.
- Cardamonin Shows Antifibrotic Activity in Human Keloid Fibroblasts: Studyhttps://practicaldermatology.com/news/cardamonin-shows-antifibrotic-activity-in-human-keloid-fibroblasts-study/2488327/Cardamonin demonstrated antifibrotic activity in human keloid fibroblasts by suppressing transforming growth factor β1 (TGF-β1)/Smad signaling, according to new in vitro research in the Journal of Drugs in Dermatology.
- Study Finds Racial Variation in Keloid Treatmenthttps://practicaldermatology.com/news/study-finds-racial-variation-in-keloid-treatment/2488178/An electronic health record analysis found differences in how keloids are treated across racial groups. In a Letter to the Editor published in the Journal of Drugs in Dermatology, investigators evaluated treatment patterns among adults with keloids using the TriNetX Research Netwo
- Merz Aesthetics Announces FDA Clearance of Ultherapy PRIME for Knee Skin Laxityhttps://practicaldermatology.com/news/merz-aesthetics-announces-fda-clearance-of-ultherapy-prime-for-knee-skin-laxity/2488072/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME (Merz Aesthetics) to improve the appearance of skin laxity on the knees, according to an announcement from the company. Merz Aesthetics said the clearance makes Ultherapy PRIME the first energy-based aesthetic device wit
- Organon Launches Sci-Fi Inspired Campaign to Spotlight VTAMA's First-in-Class Sciencehttps://practicaldermatology.com/news/organon-launches-sci-fi-inspired-campaign-to-spotlight-vtamas-first-in-class-science/2488034/Organon is launching a new multi-channel creative campaign for VTAMA (tapinarof) cream, 1% that draws on science fiction and space-inspired storytelling to engage dermatology clinicians and emphasize the product's novel mechanism of action. Built around the tagline, "It's not science ficti
- Study: Anumigilimab Well Tolerated in HS and Palmoplantar Pustulosishttps://practicaldermatology.com/news/study-anumigilimab-well-tolerated-in-hs-and-palmoplantar-pustulosis/2487876/Anumigilimab was generally well tolerated in patients with hidradenitis suppurativa (HS) or palmoplantar pustulosis (PPP), while providing preliminary signals of clinical activity in both neutrophil-driven inflammatory skin diseases, results from a Phase 1b study
- American Pharmacists Association Urges FDA to Put Patient Safety First in Peptide Reviewhttps://practicaldermatology.com/news/apha-urges-fda-to-put-patient-safety-first-in-peptide-review/2487836/The American Pharmacists Association (APhA) is urging the US Food and Drug Administration (FDA) to prioritize patient safety, scientific evidence, and regulatory oversight in its decision-making process, according to
- FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With ADhttps://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-005-in-infants-with-atopic-dermatitis/2487703/The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to mode
- FDA Expands ZORYVE Cream Approval to Children as Young as 2 Years With Plaque Psoriasishttps://practicaldermatology.com/news/fda-expands-zoryve-cream-approval-to-children-as-young-as-2-years-with-plaque-psoriasis/2487622/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) expanding the indication for ZORYVE (roflumilast) cream 0.3% to include the topical treatment of plaque psoriasis, including intertriginous areas, in children as young as 2 yea